Reports & White Papers

This new whitepaper provides valuable insights for leaders looking to optimize the impact of GLP-1 investments

New survey of 300 PCPs, endocrinologists and obesity-certified specialists explores what’s really happening between the patients asking for weight loss drugs and the physicians supporting them.

Insights for building a GLP-1 strategy and optimizing for cost and member experience.

60 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders weigh in on the growing GLP-1 cost crisis

Find out why leaders are saying goodbye to management programs that lack outcomes and ROI, and making the switch to reversal for diabetes and obesity.

A new survey of 80 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders shines a light on the growing GLP-1 cost crisis

A new strategy toolkit to help benefits leaders evaluate solutions to address metabolic health, including sample RFP questions.

A new national survey shines a light on what older adults with type 2 diabetes want from their Medicare Advantage plan.

How do health disparities contribute to higher prevalence and worsening outcomes in type 2 diabetes, and how can we make more equitable care a reality?

The Validation Institute has now awarded Virta three distinct validations for savings, outcomes and comprehensive program.

Is it possible to reverse diabetes? New research says yes. Go behind the scenes of the revolution happening in diabetes care.

Validation Institute's analysis finds that Virta's diabetes reversal treatment drives estimated medication cost savings of nearly $6k per patient over 2 years.